PROTACs have helped redefine what may be possible in drug discovery. By harnessing the ubiquitin-proteasome system to ...

The FDA's approval of vepdegestrant marks a groundbreaking shift in cancer therapy by introducing PROTAC technology for advanced breast cancer treatment.

As an added bonus, ProTac can be set to a "flicker mode" in which the PDLC continuously (and rapidly) switches back and forth between its transparent and opaque states. This allows the system to ...

Researchers have developed an improved type of PROTAC that has enhanced intracellular accumulation and functions, not only as a degrader, but also as an inhibitor of the target protein. Cancer ...

PROTAC activates the cell's own protein disposal system. Credit: MPI of Molecular Physiology Most diseases are caused by proteins that have spun out of control. Unfortunately, so far, conventional ...

Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027" report has been added to ResearchAndMarkets.com's offering.

Figure 1: The crystal structure of the Brd4 BD2 –MZ1–VHL–ElonginC–ElonginB complex. We put forth a model for how cooperative recruitment of a target close to an E3 ligase in a ternary complex by a ...

A promising strategy to reduce the impact of viral infectious diseases, such as influenza, is the use of attenuated, live viruses as vaccines. However, the usefulness of traditional live-attenuated ...

An orally bioavailable androgen receptor PROTAC, developed using a protein degradation technology, was effective in lowering tumor burden in mice bearing human castration-resistant prostate cancer, ...

Researchers from two Technion faculties have jointly developed a new compound and demonstrated its effectiveness against ...

The oncology market for PROTACs is projected to reach $3.7 billion by 2030, even though there are no FDA approved therapies currently. Protein homeostasis is critical for physiology of cell and their ...

Cancer therapies sometimes involve drugs that mediate the breakdown of specific intracellular proteins that participate in cancer formation and proliferation. Proteolysis-targeting chimeras or PROTACs ...